Vaxart (VXRT) Registration filing summary

Company overview and business model

• Clinical-stage biotech focused on oral recombinant vaccines using a proprietary tablet-based platform targeting infectious diseases such as norovirus, coronavirus (COVID-19), influenza, and preclinical HPV therapeutic vaccines.

• Oral vaccines are designed for broad, durable immune responses and convenient administration, aiming to improve patient acceptance and distribution efficiency.

• Pipeline includes bivalent norovirus, COVID-19 (including XBB and KP.2 strains), trivalent influenza, and HPV therapeutic candidates.

Financial performance and metrics

• For the year ended December 31, 2025: total revenue was $237.3M, up from $28.7M in 2024, driven by government contracts and a new license agreement.

• Net income for 2025 was $16.3M, compared to a net loss of $66.9M in 2024.

• As of March 31, 2026, cash, cash equivalents, and short-term investments totaled $61.0M, with a projected cash runway into Q2 2027.

• Research and development expenses for 2025 were $201.6M, up 172% year-over-year, mainly due to COVID-19 clinical trial costs.

Use of proceeds and capital allocation

• May receive up to $25M in gross proceeds from sales of common stock to Lincoln Park Capital under a committed equity line, with proceeds intended for working capital and general corporate purposes, including R&D.

• Management has broad discretion over use of proceeds; funds may be invested in interest-bearing securities pending use.